News

Recently, Cortex has received $1,000,000 from Servier for the option to expand its rights for CX1632. As per the terms of the agreement, if Servier exercises the option

Earlier in December 2008, ProStrakan Group, a wholly owned subsidiary of Kyowa Hakko Kirin, has licensed Canadian rights for Abstral to Paladin. Paladin Labs president and CEO Jonathan

Cacciuttolo was MedImmune, Medarex Technical Operations vice president, and was recently president and CEO of PERCIVIA. The company also appointed Ben Machielse and Robert Gailus to the Board

The results of the trial suggested shorter and less severe periods of respiratory depression when treated with MoxDuo IR, compared to morphine or oxycodone. The trial involved approximately

The Phase I clinical trial of VIA-3196 will assess the safety, pharmacokinetics and pharmacodynamics of VIA-3196 in healthy subjects. The company expects to recruit around 72 patients in

RXT 110 has agreed to make payments aggregating to $150,000 over the course of the next four months for an interim license. During the term of the interim

The trial is intended to evaluate the safety, bioactivity and anti-tumor effect of patients’ own T cells that have been genetically modified to express a high affinity T

ALS-2200 and ALS-2158, currently in preclinical development, are designed to inhibit the replication of the hepatitis C virus by acting on the NS5B polymerase. As part of the

The Phase I trial is expected to assess safety along with the immunological and biological effects of ZIN ATI-001 in patients with melanoma. ZIN ATI-001 employs an adenoviral